No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

EarlySense Names John Dragovits as New SVP of Strategic Partnerships

Editor: What To Know

  • Matt Johnson, EarlySense CEO notes, “Partner collaboration has played an important role in EarlySense's growth and has been instrumental in helping us reach our goal of establishing contact-free continuous monitoring as a standard of care.
  • “EarlySense is a recognized innovator within the patient monitoring markets, and has played an important role in advancing patient safety and outcomes in healthcare facilities worldwide,” said Dragovits.
  • He was also held health system senior executive roles, having served as Chief Financial Officer and Chief Operating Officer of Dallas' Children's Health and Executive VP and CFO of Parkland Health &.

Matt Johnson, EarlySense CEO notes, “Partner collaboration has played an important role in EarlySense’s growth and has been instrumental in helping us reach our goal of establishing contact-free continuous monitoring as a standard of care.” Johnson added, “We look forward to tapping into John’s expertise to strengthen current strategic partnerships and help bring in new relationships that will enable us to continue to elevate patient safety and care.”

John Dragovits has more than 30 years of experience as a healthcare and healthcare IT executive leader. He previously served in VP roles with electronic health records companies Cerner Corporation (Nasdaq: CERN) as well as Senior Vice President and General Manager of Revenue Cycle at Allscripts (Nasdaq: MDX). He was also held health system senior executive roles, having served as Chief Financial Officer and Chief Operating Officer of Dallas’ Children’s Health and Executive VP and CFO of Parkland Health & Hospital System.  Mr. Dragovits is a former U.S. Navy Officer as well as a CPA and holds graduate and undergraduate degrees from Rice University.

“EarlySense is a recognized innovator within the patient monitoring markets, and has played an important role in advancing patient safety and outcomes in healthcare facilities worldwide,” said Dragovits. “I am honored to join the EarlySense team and to explore new avenues to bring contact-free continuous monitoring to even more patients, families and health teams.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy